Group sequential designs for three-arm 'gold standard' non-inferiority trials with fixed margin

Statistics in Medicine

Volumn 32, Issue 28, 2013, Pages 4875-4889

  Schlömer, Patrick ^a   Brannath, Werner ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

Approximately optimal boundaries; Group sequential design; Noninferiority trial; Three arm design; Wang Tsiatis boundaries

Indexed keywords

CORTICOSTEROID; PLACEBO;

ALGORITHM; ANALYTICAL ERROR; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; GROUP SEQUENTIAL DESIGN; HUMAN; METHODOLOGY; NON INFERIORITY TRIAL; PLACEBO EFFECT; PROCESS OPTIMIZATION; QUANTITATIVE STUDY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL;

APPROXIMATELY OPTIMAL BOUNDARIES; GROUP SEQUENTIAL DESIGN; NONINFERIORITY TRIAL; THREE-ARM DESIGN; WANG-TSIATIS BOUNDARIES;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; FORCED EXPIRATORY VOLUME; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84887149876     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5950     Document Type: Article

References (46)

1. D'Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22(2):169-186.
2. ICHExpert Working Group. Choice of control group and related issues in clinical trials E10, 2000.
3. CHMP. Guideline on the choice of the non-inferiority margin, London, 2005.
4. CPMP. Note for guidance on the clinical investigation of medicinal products indicated in the treatment of asthma, London, 2003.
5. CHMP. Guideline on clinical investigation of medicinal products indicated for the treatment of panic disorder, London, 2005.
6. CHMP. Guideline on clinical investigation of medicinal products for the treatment of migraine, London, 2007.
7. Koch A, Röhmel J. Hypothesis testing in the 'gold standard' design for proving the efficacy of an experimental treatment relative to placebo and a reference. Journal of Biopharmaceutical Statistics 2004; 14(2):315-325.
8. Röhmel J. Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine 1998; 17(15-16):1703-1714.
9. Koch GG, Tangen CM. Nonparametric analysis of covariance and its role in noninferiority clinical trials. Drug Information Journal 1999; 33(4):1145-1159.
10. Pigeot I, Schäfer J, Röhmel J, Hauschke D. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. Statistics in Medicine 2003; 22(6):883-899.
11. Tang ML, Tang NS. Tests of noninferiority via rate difference for three-arm clinical trials with placebo. Journal of Biopharmaceutical Statistics 2004; 14(2):337-347.
12. Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in Medicine 2007; 26(2):253-273.
13. Hasler M, Vonk R, Hothorn LA. Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity. Statistics in Medicine 2008; 27(4):490-503.
14. Dette H, Trampisch M, Hothorn LA. Robust designs in noninferiority three-arm clinical trials with presence of heteroscedasticity. Statistics in Biopharmaceutical Research 2009; 1(3):268-278.
15. Gamalo MA, Muthukumarana S, Ghosh P, Tiwari RC. A generalized p-value approach for assessing noninferiority in a three-arm trial. Statistical Methods in Medical Research 2013; 22(3):261-277.
16. Mielke M, Munk A, Schacht A. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints. Statistics in Medicine 2008; 27(25):5093-5110.
17. Schwartz TA, Denne JS. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials. Statistics in Medicine 2006; 25(19):3396-3406.
18. Li G, Gao S. A group sequential type design for three-arm non-inferiority trials with binary endpoints. Biometrical Journal 2010; 52(4):504-518.
19. Munzel U. Nonparametric non-inferiority analyses in the three-arm design with active control and placebo. Statistics in Medicine 2009; 28(29):3643-3656.
20. Gosh P, Nathoo FS, Gönen M, Tiwari RC. Assessing noninferiority in a three-arm trial using the Bayesian approach. Statistics in Medicine 2011; 30(15):1795-1808.
21. Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the 'gold standard' design. Biometrical Journal 2005; 47(6):782-786.
22. Lewis JA. Discussion on "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):787-789.
23. Röhmel J. Discussion on "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):790-791.
24. Koch A. Discussion on "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):792-793.
25. Mehrotra DV. Discussion on "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):794.
26. Hung HMJ. Discussion on "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):795-796.
27. Hauschke D, Pigeot I. Rejoinder to "Establishing efficacy of a new experimental treatment in the 'gold standard' design". Biometrical Journal 2005; 47(6):797-798.
28. Röhmel J. On confidence bounds for the ratio of net differences in the "gold standard" design with reference, experimental, and placebo treatment. Biometrical Journal 2005; 47(6):799-806.
29. Röhmel J, Pigeot I. A comparison of multiple testing procedures for the gold standard non-inferiority trial. Journal of Biopharmaceutical Statistics 2010; 20(5):911-926.
30. Hida E, Tango T. On the three-arm non-inferiority trial including a placebo with a prespecified margin. Statistics in Medicine 2011; 30(3):224-231.
31. Kwong KS, Cheung SH, Hayter AJ, Wen MJ. Extension of three-arm non-inferiority studies to trials with multiple new treatments. Statistics in Medicine 2012; 31(24):2833-2843.
32. Kwong KS, Cheung SH, Hayter AJ. Step-up procedures for non-inferiority tests with multiple experimental treatments. Statistical Methods in Medical Research 2013. [Epub ahead of print] DOI: 10.1177/0962280213477767.
33. Röhmel J, Pigeot I. Statistical strategies for the analysis of clinical trials with an experimental treatment, an active control and placebo, and a prespecified fixed non-inferiority margin for the difference in means. Statistics in Medicine 2011; 30(26):3162-3164.
34. Hida E, Tango T. Response to Joachim Röhmel and Iris Pigeot. Statistics in Medicine 2011; 30(26):3165-3165.
35. Stucke K, Kieser M. A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design. Statistics in Medicine 2012; 31(28):3579-5396.
36. Maurer W, Hothorn LA, Lehmacher W. Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypotheses. In Biometrie in der chemisch-pharmazeutischen Industrie, Vollmar J (ed.). Deutscher Apotheker Verlag: Stuttgart, 1995.
37. Strassburger K, Bretz F. Compatible simultaneous lower confidence bounds for the holm procedure and other Bonferroni-based closed tests. Statistics in Medicine 2008; 27(24):4914-4927.
38. Guildbaud O. Simultaneous confidence regions corresponding to Holm's step-down procedure and other closed-testing procedures. Statistics in Medicine 2008; 50(5):678-692.
39. Byrd RH, Lu P, Nocedal J, Zhu C. A limited memory algorithm for bound constrained optimization. SIAM Journal on Scientific Computing 1995; 16(6):1190-1208.
40. Hartung J, Knapp G. Adaptive controlled noninferiority group sequential trials, TU Dortmund - Eldorado, 2009. (Available from: http://hdl.handle.net/2003/26014) [accessed 2 February 2012].
41. Tang DI, Geller NL. Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics 1999; 55(4):1188-1192.
42. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987; 43:193-200.
43. Nelder JA, Mead R. A simplex algorithm for function minimization. Computer Journal 1965; 7:308-313.
44. CHMP. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, London, 2007.
45. Hwang IH, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions. Statistics in Medicine 1990; 9(12):1439-1445.
46. Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 1987; 74(1):149-154.